Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside

Handbook of Experimental Pharmacology

Volumn 243, Issue , 2017, Pages 271-305

  Kolkhof, Peter ^a   Jaisser, Frederic ^b   Kim, So Young ^a   Filippatos, Gerasimos ^c   Nowack, Christina ^a   Pitt, Bertram ^d  

^a BAYER PHARMA AG   (Germany)

^b INSERM   (France)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chronic kidney disease; Eplerenone; Finerenone; Heart failure; Mineralocorticoid receptor antagonists; Spironolactone

Indexed keywords

ALDOSTERONE; BR 4628; EPLERENONE; FINERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NITRENDIPINE; PF 03882845; PLACEBO; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; NAPHTHYRIDINE DERIVATIVE;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CARDIAC MUSCLE CELL; CARDIORENAL SYNDROME; DIABETIC NEPHROPATHY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIUM CELL; FIBROBLAST; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PLASMA CLEARANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; VASCULAR SMOOTH MUSCLE CELL; ANALOGS AND DERIVATIVES; ANIMAL; CARDIO-RENAL SYNDROME; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; HEART STROKE VOLUME; METABOLISM; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIO-RENAL SYNDROME; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; FIBROBLASTS; HEART FAILURE; HUMANS; MACROPHAGES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; NAPHTHYRIDINES; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; STROKE VOLUME;

EID: 85020624973     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2016_76     Document Type: Chapter

References (145)

1. Albaghdadi M, Gheorghiade M, Pitt B (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 32:2626–2633.
2. Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR et al (2015) Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem 290:21876–21889.
3. Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K et al (2010a) Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 53:4300–4304.
4. Arhancet GB, Woodard SS, Iyanar K, Case BL, Woerndle R, Dietz JD et al (2010b) Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J Med Chem 53:5970–5978.
5. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268–275.
6. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. JAMA 314:884–894.
7. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H et al (2012) Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:1385–1403.
8. Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F (2016) Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J Am Soc Nephrol 27:398–404.
9. Bauersachs J, Jaisser F, Toto R (2015) Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65:257–263.
10. Bertocchio JP, Warnock DG, Jaisser F (2011) Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 79:1051–1060.
11. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK et al (2012) Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153:3416–3425.
12. Bienvenu LA, Reichelt ME, Morgan J, Fletcher EK, Bell JR, Rickard AJ et al (2015) Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult. Hypertension 66:970–977.
13. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355–1364.
14. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG et al (2015) Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 65:45–53.
15. Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S (2001) Effects of canrenone on aorta and right ventricle of the rat. J Cardiovasc Pharmacol 37:540–547.
16. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H et al (2005) Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96:1530–1536.
17. Chien YW, Hofmann LM, Lambert HJ, Tao LC (1976) Binding of spirolactones to human plasma proteins. J Pharm Sci 65:1337–1340.
18. Chun TY, Pratt JH (2005) Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol Cell Endocrinol 239:55–61.
19. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P et al (2002) Relation of aldosterone “escape” despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in CHF secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 89:403–407.
20. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology (2003) The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 24:442–463.
21. Collin M, Jaisser F (2014) Mineralocorticoid receptor modulators: a patent review (2007–2012). Expert Opin Ther Pat 24:177–183.
22. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW (2003) Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 31:1448–1455.
23. Darrow DC, Miller HC (1942) Production of cardiac lesions by repeated injections of desoxycorticosterone acetate. J Clin Invest 21:601–611
24. de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L et al (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650–656
25. de Lera AR, Bourguet W, Altucci L, Gronemeyer H (2007) Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6:811–820
26. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921–927.
27. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R et al (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162:966.e10–972.e10.
28. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR et al (2008) A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51:742–748.
29. Dinsdale C, Wani M, Steward J, O’Mahony MS (2005) Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing 34:395–398.
30. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS et al (1988) Localisation of 11 beta-hydroxysteroid dehydrogenase – tissue specific protector of the mineralocorticoid receptor. Lancet 2:986–989.
31. Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E, Schlemmer KH (2005) Fluorenone 1, 4,-dihydropyridin derivatives, WO/2005/087740. Bayer Healthcare AG, Wuppertal
32. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U et al (2010) A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 285:29932–29940.
33. Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B et al (2011) Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 300:H2035–H2043.
34. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37:2105–2114, PMID: 27130705.
35. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G et al (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123:400–408.
36. Fritsch Neves M, Schiffrin EL (2003) Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 5:59–65.
37. Fuller PJ, Young MJ (2005) Mechanisms of mineralocorticoid action. Hypertension 46:1227–1235.
38. Funder JW (1994) Enzymes and receptors: challenges and future directions. Steroids 59:164–169.
39. Funder JW (2001) Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens 10:227–230.
40. Funder JW (2004) Is aldosterone bad for the heart? Trends Endocrinol Metab 15:139–142.
41. Funder JW (2005a) RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121–125.
42. Funder JW (2005b) Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 1:4–5.
43. Funder JW (2009) Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53:286–290.
44. Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583–585.
45. Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27–31.
46. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A et al (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119–123.
47. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al (2013) Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 127(1):e6–e245.
48. Gómez AM, Rueda A, Sainte-Marie Y, Pereira L, Zissimopoulos S, Zhu X et al (2009) Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 119:2179–2187.
49. Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Höft B et al (2016) Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol 67:402–411.
50. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115:1754–1761.
51. Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP et al (2016) Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension 67:717–723.
52. Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S (2016) Pharmacokinetics of the novel Non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev. doi:10.1002/cpdd.263.
53. Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ, Tesch GH (2014) Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 25:2231–2240.
54. Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, Kato S (2013) Nuclear receptors in bone physiology and diseases. Physiol Rev 93:481–523.
55. Inspra Drug Approval Package (2003) Pharmacological Review Inspra Drug Approval Package 21-437/S-002, FDA US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-437S002_Inspra_Pharmr.pdf
56. Jaisser F, Farman N (2016) Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev 68:49–75.
57. Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT et al (2015) Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension 66:1159–1167.
58. Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X et al (2010) Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf 19:266–272.
59. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543–551.
60. Kagawa CM, Cella JA, Van Arman CG (1957) Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126:1015–1016.
61. Karim A (1978) Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev 8:151–188.
62. Kim HY, Bae EH, Ma SK, Kim SW (2014) Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with proteinuria. Kidney Blood Press Res 39:573–580.
63. Kolkhof P, Borden SA (2012) Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 350:310–317.
64. Kolkhof P, Flamme I, Figueroa-Pérez S, Baerfacker L, Hartmann E, Rinke M, Schäfer S (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur Heart J 27(Suppl 1):110.
65. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L et al (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64:69–78.
66. Kolkhof P, Nowack C, Eitner F (2015) Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 24:417–424.
67. Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M (2010) The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 635:49–55.
68. Landau RL, Lugibihl K (1958) Inhibition of the sodium-retaining influence of aldosterone by progesterone. J Clin Endocrinol Metab 18:1237–1245.
69. Landau RL, Bergenstal DM, Lugibihl K, Kascht ME (1955) The metabolic effects of progesterone in man. J Clin Endocrinol Metab 15:1194–1215.
70. Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schäfers HJ et al (2014) The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:6656–6668.
71. Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G (2016) Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone – results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol 30:172–184.
72. Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, Sun XN et al (2014) Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One 9(10), e110950.
73. Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA (2015) Finerenone: thirdgeneration mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 24:1123–1135.
74. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71:503–510.
75. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, Barreto F et al (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57:746–754.
76. Lother A, Moser M, Bode C, Feldman RD, Hein L (2015) Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol 55:8.1–8.24.
77. Lother A, Furst D, Bergemann S, Gilsbach R, Grahammer F, Huber TB et al (2016) Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension 67:130–138.
78. Ma FY, Han Y, Nikolic-Paterson DJ, Kolkhof P, Tesch GH (2015) Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628. PLoS One 10, e0145666.
79. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al (2013) EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15:808–817.
80. Mann N (1963) Gynecomastia during therapy with spironolactone. JAMA 184:778–780.
81. Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, Fabbri A et al (2012) The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol 350:281–288.
82. Matsui T, Takeuchi M, Yamagishi S (2010) Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)- exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 396:566–570.
83. Mavrakanas TA, Gariani K, Martin PY (2014) Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy. Eur J Intern Med 25:173–176.
84. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD (2002) Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39:60–69.
85. Meyer WJ, Nichols NR (1981) Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem 14:1157–1168.
86. Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW et al (2010) Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 53:5979–6002.
87. Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137–1146.
88. Mulder P, BarreraChimal J, El Moghrabi S, Kolkhof P, Ouvrard-Pascaud A, Jaisser F (2016) Finerenone improves diastolic function in a preclinical model of type2 diabetes mellitus. Eur Heart J 37(Abstract Supplement):829.
89. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H et al (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47:656–664.
90. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N et al (2010) The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 24:2454–2463.
91. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M et al (2008) Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 156:662–673.
92. Orena S, Maurer TS, She L, Eudy R, Bernardo V, Dash D et al (2013) PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol 4:115.
93. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, Perrier R, Soukaseum C, Nguyen Dinh Cat A et al (2005) Conditional mineralocorticoid receptor expression in the heart leads to lifethreatening arrhythmias. Circulation 111:3025–3033.
94. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (3):251–259.
95. Parthasarathy HK, Ménard J, White WB, Young WF Jr., Williams GH, Williams B et al (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 29:980–990.
96. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N et al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34–42.
97. Piotrowski DW (2012) Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 55:7957–7966.
98. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717.
99. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321.
100. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P et al (2012) Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 14:668–6675.
101. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453–2463.
102. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392.
103. Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H et al (2015) Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone versus eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail 17:224–232.
104. Platt D, Pauli H (1972) Studies on organ- and subcellular distribution of [3H]spironolactone in animals [in German]. Arzneimittelforschung 22:1801–1802.
105. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al; Authors/Task Force Members; Document Reviewers (2016) 2016. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. doi:10.1002/ejhf.592.
106. Reichstein T, von Euw J (1938) Über Bestandteile der Nebennierenrinde. Isolierung der Substanzen Q (Desoxy-Corticosteron) und R sowie weiterer Stoffe. Helvet Chim Acta 21:1197–1210.
107. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54:537–543.
108. Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ et al (2012) Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/saltmediated inflammation and cardiac fibrosis. Hypertension 60:1443–1450.
109. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ (2014) Endothelial cell mineralocorticoid receptors regulate DOC/salt-mediated cardiac remodeling and vascular reactivity, but not blood pressure. Hypertension 63:1033–1040.
110. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA et al (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802–H1810.
111. Rogerson FM, Fuller PJ (2000) Mineralocorticoid action. Steroids 65:61–73.
112. Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M et al (1994) Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24:583–591.
113. Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA (2016) Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens 34:11–19.
114. Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al (2014) Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol 40:572–581.
115. Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T et al (2016) ARTS-HF Japan Study Group. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circ J 80:1113–1122.
116. Schupp N, Kolkhof P, Queisser N, Gärtner S, Schmid U, Kretschmer A et al (2011) Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25:968–978.
117. Schwenk MH, Hirsch JS, Bomback AS (2015) Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis 22:123–132.
118. Selye H (1942) Production of nephrosclerosis by overdosage with desoxycorticosterone acetate. Can Med Assoc J 47:515–519.
119. Selye H (1946) The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 6:117–230.
120. Selye H (1955) Anticortisol action of aldosterone. Science 121:368–369.
121. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295:2465–2468.
122. Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10:23–29.
123. Simpson SA, Tait JF (1953) Memoirs of the Society for Endocrinology, No. 2. The determination of adrenal cortical steroids and their metabolites. Dennis Dobson, Ltd., London, p 9.
124. Simpson SA, Tait JF, Wettstein A, Neher R, Euw J, Schindler O, Reichstein T (1954) Constitution of aldosterone, a new mineralocorticoid. Experientia 10:132–133.
125. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:457–465.
126. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K et al (2005) Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 336:163–167.
127. Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E (1992) Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 102:1680–1685.
128. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D (2004) How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 10:297–303.
129. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730–1736.
130. Tamargo J, Solini A, Ruilope LM (2014) Comparison of agents that affect aldosterone action. Semin Nephrol 34:285–306.
131. Tarjus A, Martínez-Martínez E, Amador C, Latouche C, El Moghrabi S, Berger T et al (2015) Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66:158–166.
132. Thorn GW, Engel LL (1938) The effect of sex hormones on the renal excretion of electrolytes. J Exp Med 68:299–312.
133. Thorn GW, Howard RP, Emerson K (1939) Treatment of Addison’s disease with desoxycorticosterone acetate, a synthetic adrenal cortical hormone (preliminary report). J Clin Invest 18:449–467.
134. Thosar SS, Gokhale RD, Tolbert DS (2003) Immediate Release Eplerenone Compositions, US 6, 558, 707(B1). G.D. Searle & Co., US
135. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M et al (2008) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29(3):339–347.
136. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G et al (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350–3364.
137. Weinberger MH, Roniker B, Krause SL, Weiss RJ (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15:709–716.
138. Weir RA, Tsorlalis IK, Steedman T, Dargie HJ, Fraser R, McMurray JJ, Connell JM (2011) Aldosterone and cortisol predict medium-term left ventricular remodeling following myocardial infarction. Eur J Heart Fail 13:1305–1313.
139. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Adhere Scientific Advisory Committee and Investigators (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76–84.
140. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH et al (2013) 2013. ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240–e327.
141. Yang J, Young MJ (2016) Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol 27:78–85.
142. Yu L, Helms MN, Yue Q, Eaton DC (2008) Single-channel analysis of functional epithelial sodium channel (ENaC) stability at the apical membrane of A6 distal kidney cells. Am J Physiol Renal Physiol 295:F1519–F1527.
143. Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102:2700–2706.
144. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21.
145. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K et al (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33:2782–2795